SWOG clinical trial number
SWOG-9104
Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II
Closed
Phase
Accrual
65%
Published
Abbreviated Title
Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II
Activated
09/01/1992
Closed
09/01/1994
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1997
Phase II evaluation of doxorubicin/vinblastine combined wtih inhibitors (trifluoperazine/verapamil) of p-glycoprotein in patients with advanced renal carcinoma.
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase